Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naive Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery

被引：0

作者：

Mascarenhas, John ^{[1
]}

Rampal, Raajit K. ^{[2
]}

Vannucchi, Alessandro M. ^{[3
]}

Gupta, Vikas ^{[4
]}

Oh, Stephen T. ^{[5
]}

Kuykendall, Andrew T. ^{[6
]}

Mesa, Ruben ^{[7
]}

Kiladjian, Jean-Jacques ^{[8
]}

Talpaz, Moshe ^{[9
]}

Kremyanskaya, Marina ^{[9
]}

Scandura, Joseph ^{[10
]}

Kraeft, Tabea ^{[11
]}

Eliane, Jean-Pierre ^{[12
]}

Chang, Tzuu-Wang ^{[12
]}

Cui, Jike ^{[12
]}

Kuffer, Christian ^{[11
]}

Boxhammer, Rainer ^{[11
]}

Harrison, Claire ^{[13
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA

[3] Univ Florence, Dept Clin & Expt Med, Florence, Italy

[4] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada

[5] Washington Univ, Sch Med St Louis, St Louis, MO USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Wake Forest Univ, Atrium Hlth Wake Forest Baptist Comprehens Canc C, Sch Med, Winston Salem, NC USA

[8] Univ Paris, Clin Invest Ctr, Hop St Louis, Paris, France

[9] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA

[10] Cornell Med, Div Hematol & Oncol, Richard T Silver MD Myeloproliferat Neoplasms Ctr, New York, NY USA

[11] MorphoSys AG, Planegg, Germany

[12] Constellation Pharmaceut Inc, Boston, MA USA

[13] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

MPN; myelofibrosis; clinical trial; pelabresib; bone marrow microenvironment; phase; 3;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MPN-136

引用

页码：S417 / S418

页数：2

共 50 条

[1] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Mascarenhas, John
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Lavie, David
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna Maria
Wu, Manlei
Brown, Barbara
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
[2] Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naive Patients with Myelofibrosis
Mascarenhas, John O.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Li, Qing
Brown, Barbara
Jegg, Anna-Maria
Harrison, Claire
Rampal, Raajit
BLOOD, 2024, 144 : 3178 - 3180
[3] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, Claire N.
Gupta, Vikas K.
Gerds, Aaron T.
Rampal, Raajit
Verstovsek, Srdan
Talpaz, Moshe
Kiladjian, Jean-Jacques
Mesa, Ruben
Kuykendall, Andrew T.
Vannucchi, Alessandro M.
Palandri, Francesca
Grosicki, Sebastian
Devos, Timothy
Jourdan, Eric
Wondergem, Marielle J.
Al-Ali, Haifa Kathrin
Buxhofer-Ausch, Veronika
Alvarez-Larran, Alberto
Patriarca, Andrea
Kremyanskaya, Marina
Mead, Adam J.
Akhani, Sanjay
Sheikine, Yuri
Colak, Gozde
Mascarenhas, John
FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997
[4] Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Scandura, Joseph M.
Lavie, David
Harris, Morgan
Kays, Sarah-Katharina
Li, Qing
Boxhammer, Rainer
Brown, Barbara
Jegg, Anna-Maria
Harrison, Claire N.
Mascarenhas, John
NATURE MEDICINE, 2025,
[5] BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naive or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Harrison, Claire
Bose, Prithviraj
Rampal, Raajit K.
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Hobbs, Gabriela
Talpaz, Moshe
Vannucchi, Alessandro
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Hoffman, Ron
Salama, Mohamed E.
Chen, Dong
Taverna, Pietro
Chang, Alex
Colak, Gozde
Klein, Sandra
Gupta, Vikas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S335 - S336
[6] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna-Maria
Li, Qing
Brown, Barbara
Harrison, Claire N.
Mascarenhas, John
BLOOD, 2023, 142
[7] Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis
Rampal, Raajit
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron Thomas
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Kuykendall, Andrew Tucker
Mesa, Ruben A.
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Wu, Manlei
Brown, Barbara
Harrison, Claire
Mascarenhas, John
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Devos, T.
Rampal, R.
Vannucchi, A.
Passamonti, F.
Mead, A.
Kremyanskaya, M.
Somervaille, T.
Wondergem, M.
Hoffman, R.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Verstovsek, S.
Gupta, V.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 6
[9] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
Passamonti, Francesco
Foran, James M.
Tandra, Anand
De Stefano, Valerio
Fox, Maria Laura
Mattour, Ahmad Hatem
McMullin, Mary Frances
Perkins, Andrew
Rodriguez-Macias, Gabriela
Sibai, Hassan
Qin, Qin Q.
Potluri, Jalaja
How, Jonathan B.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta, Vikas
Kremyanskaya, Marina
Mascarenhas, John
Palandri, Francesca
Patriarca, Andrea
Devos, Timothy
Harrison, Claire
Passamonti, Francesco
Rampal, Raajit
Mead, Adam
Scandura, Joseph
Hobbs, Gabriela
Talpaz, Moshe
Granacher, Nikki
Somervaille, Tim
Hoffman, Ronald
Bose, Prithviraj
Colak, Gozde
Shao, James
Cui, Jike
Bobba, Suresh
Luptakova, Katarina
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S362 - S362

← 1 2 3 4 5 →